Pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) due to systemic-to-pulmonary shunting is associated with a high risk of morbidity and mortality. In this study we evaluated 4 years treatment effect of bosentan on exercise capacity and quality of life and survival rates in 64 adult patients with PAH associated with CHD, including patients with Down syndrome (DS). All patients were evaluated at baseline and during follow-up with laboratory tests, 6-minute walk test, quality of life questionnaires, and Doppler echocardiography. In total, 13 patients (20%) died during 4-years of follow-up; 4 patients with DS and 9 patients without DS. Mean follow-up of all patients treated with bosentan was 3.5 ± 1.2 year. We analyzed treatment efficacy separately within patients without DS (n=34) and patients with DS (n=30). Mean 6 minute walking distance (6MWD) in patients without DS significantly increased at 6 months from 417 ± 108 to 458 ± 104 m (+41 m; p=0.002) and significant improvement continued to exist during at least 2.5 years of follow-up (p=0.003). Moreover, stroke volume increased significantly (p=0.02). In the patients with DS, 6-MWD, stroke volume and quality of life remained stable during treatment. In this study we demonstrate a prolonged beneficial effect of bosentan treatment on exercise capacity, stroke volume and quality of life in patients without DS. However the mortality rate of 20% of patients after 4 years of follow-up remains high.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare syndrome of dyspnoea, fatigue, chest pain and syncope caused by a progressive increase in pulmonary vascular resistance and defined by a sustained elevation of pulmonary arterial pressure to more than 25 mm Hg at rest and a capillary wedge pressure of 15 mmHg or less. 1 It is clinically characterised by decreased functional capacity, right ventricular failure and a shortened life expectancy. 2, 3 PAH due to congenital heart disease (CHD) with systemic to pulmonary shunt is a major subgroup of patients with PAH. 4 CHD-PAH is a result of systemic to pulmonary shunting and chronic increased flow that ultimately results in adaptations of pulmonary vasculature and endothelial dysfunction. The advanced stage is called Eisenmenger syndrome which forms a small percentage (1%) of all CHD patients. 5 Until recently, treatment options for patients with pulmonary arterial hypertension were limited. A major breakthrough in the treatment of patients with PAH has been the introduction of the oral endothelin receptor antagonist bosentan. Short-term treatment with bosentan has shown to improve morbidity of patients with PAH, including those with Eisenmenger syndrome. 6 However, results on longer-term treatment response are equivocal and data on quality of life is limited despite the importance of quality of life assessment. 7, 8 Although several studies reported a persistent beneficial effect of bosentan on exercise capacity [9] [10] [11] [12] [13] , other studies reported a gradual decline of exercise capacity to baseline values after 2 years of bosentan treatment. [14] [15] [16] [17] In patients with Down syndrome (DS), the treatment effect of bosentan is largely unknown. 18 The aim of our study was to evaluate the long term efficacy of bosentan treatment and 4 years survival rates of adult patients with PAH associated with CHD with and without the DS.
METHODS

Study population
Adult patients with Eisenmenger syndrome and the following congenital heart defects were included: septal defects, patent arterial duct and created aortopulmonary shunts in cyanotic congenital heart disease (Waterston/Potts shunt 
Study design
All patients were evaluated according to a standardized treatment protocol with clinical examination (determination of functional class) Doppler echocardiography, a six minute walk test (6MWT), laboratory tests (including haemoglobin, creatinine, uric acid, and N-terminal pro-B natriuretic peptide (NT-pro-BNP)) and quality of life questionnaires These tests (except for echocardiogram) were administered at baseline and after 3, 6, 9 and 12 months follow-up and from then on twice yearly. All tests were performed on the same day. Data on events such as death were taken from the databases of the participating hospitals.
Submaximal exercise capacity was assessed using the 6-MWT, according to the guidelines of the American Thoracic Society with continuous pulse oximetry monitoring. 19 To exclude the effect of a learning curve, the 6-MWD at baseline was performed twice, using the second test as baseline value. In previous research, the 6MWT appeared to be an invalid test to examine exercise capacity in patients with DS. 20 Therefore in this study 6MWTs were not analyzed to investigate treatment effect in patients with DS. 
RESULTS
Baseline characteristics
Between January 2005 and July 2010, 70 patients were enrolled in the treatment protocol. Overall, 64 patients (30 with DS) received bosentan and were included in this study. Four patients refused treatment initiation and reimbursement of bosentan by the health insurance was rejected in 2 patients. The median follow-up duration was 42 months (range 2 to 64 months). 
Survival analysis
In total, 13 people died during 4-years of follow-up, 4 patients with DS and 9 patients without DS. Table 2 shows detailed information about the deceased patients. Survival rates in patients without DS at 1-, 2-and 4-years were respectively 88%, 88% and 72%, and for patients with DS 97%, 93% and 80%. Figure 1 shows the Kaplan-Meier 
Six minute walk test
Bosentan showed a prolonged significant improvement of the 6MWD in the patient group without DS (see figure 2) . The mean 6MWD maximally increased with +41m In general, most echocardiographic parameters remained unchanged in both groups of patients during follow-up. However, analyses of the left ventricle in patients without DS showed that mean stroke volume significantly increased (+13.5 ml) after 3 years follow-up (p=0.02). Even so, mean cardiac output tended to increase without reaching significance. 
Laboratory testing
Baseline levels of laboratory test are shown in table 1. The mean logNT-pro-BNP level decreased significantly from 2.8 ± 0.5 to 2.7m ± 0.5 ng/L (p=0.03) at 3 months, at 6 months (p=0.02) and 1 year (p=0.05) of treatment (see Figure 3) . After 1 year follow-up, logNT-pro-BNP levels returned to baseline levels and tended to deteriorate (although not statistically significantly). Haemoglobin, creatinine and uric acid levels did not change significantly. No correlation could be found between baseline 6MWD or change in 6MWD during bosentan treatment and baseline logNT-pro-BNP. In addition, no relations were found between changes in 6MWD and haemoglobin, creatinine or uric acid levels. 
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NYHA classification
NYHA classification was assessed at baseline and at the end-of-study visit. The majority of patients were in NYHA class III at baseline. NYHA class had improved in 23% of patients, had deteriorated in 25% of patients and had remained stable in 52% of patients (see table 4 ). NYHA class did not change significantly during follow-up (p=0.07). Although a trend towards worsening in NYHA class was shown in patients without DS. NYHA; new york heart association class NYHA class did not change significally during follow-up assessed by the Wilcoxon signed-rank test
Safety
Induction of oral bosentan therapy was well tolerated in both patient groups, without signs of decreasing oxygen saturation. One patient without DS experienced severe throat pain and dose was reduced to twice daily 62.5 mg. in another patient without DS, who experienced headaches shortly after bosentan initiation, dose was ultimately reduced to 32.5mg twice daily. A third patient without DS had an asymptomatic increase in liver transaminases (>3 times upper limit of normal), which resolved within 2 weeks after dose reduction, whereupon the 125 mg twice daily dose was resumed without reoccurrence.
DISCUSSION
This is the first study reporting on the effect of 4 years of bosentan treatment on exercise capacity, stroke volume and quality of life in adult patients with PAH associated with CHD. We showed a prolonged increase in exercise capacity after 2.5 years of treatment in patients without DS. A beneficial effect was still present up to 4 years of treatment, although failed to reach statistical significance due to low patient numbers. In 2006, the BREATHE-5 study was the first randomised controlled trial which studied the effect of bosentan in patients with Eisenmenger syndrome. Mean improvement of 6MWD in 37 patients was +53m after 4 months of treatment and the overall improvement was +61m in 26 patients after 10 months of treatment in BREATHE-5 combined with the open-label extension study. 6, 21 Two longer-term follow-up studies found a significant increase and maintained effect in 6MWD after 1 year and 2 years of bosentan treatment. 9, 10 However, 2 other studies only reported a short term efficacy of bosentan followed by gradual return to baseline after 2 year follow-up. 14,15 Duffels et al hypothesized that this decline in 6-MWD during treatment might be due to the development of tolerance for bosentan. 15 Our 4 years follow-up study demonstrates that a prolonged effect of bosentan on exercise capacity can be expected in patients with PAH due associated with CHD. We believe clinical stability at 4 year follow-up could be considered successful in a disease that is associated with clinical deterioration.
Additionally, quality of life improved significantly and a remaining effect was shown after 3 years of treatment in patients without DS. Although some quality of life domains remained stable during treatment, others improved significantly. The physical domains role physical and physical functioning increased significantly during bosentan treatment, indicating that patients experienced fewer problems at work and during daily activities. In patients with PAH, health related quality of life has been shown to be significantly impaired and evaluation of quality of life is of great importance. 22, 23 Moreover, from the patients' perspective, quality of life is one of the most important measures of treatment effect.
We evaluated treatment effect in patients with DS as PAH is particularly common in these patients. 24 In the 2 years follow-up study of Duffels et al, a change on 6MWD was not found due to the disputable validity of the 6MWD in patients with DS. 15, 20 The 6MWD appeared to be related to the level of intellectual disability. A significant change of 13.5 ml in mean stroke volume was found after 3 years follow-up (p=0.02) in patients without DS. This corresponds to the recent findings of van Wolferen et al who showed that stroke volume is an important hemodynamic parameter to reflect therapeutic changes during follow-up of PAH. 25, 26 In the study of van Wolferen et al, 111 patients with PAH (90% idiopathic PAH and PAH associated with connective tissue disease) were evaluated with cardiac MRI to assess stroke volume at baseline and after 1 year. The minimal important difference was determined using statistical methods and a 10 ml change in stroke volume during follow-up was considered to be clinical relevant. 26 In this respect, the 13.5 ml increase of stroke volume we found in our study can be considered of clinical importance.
Patients with Eisenmenger syndrome are at high risk of death 27 and despite the widespread use of advanced therapies very little evidence on survival benefits is currently available. Survival analysis in the present study showed that after 4 years of follow-up, 20% of the patients died. Dimopoulos et al found a much lower mortality rate in their retrospective study. 28 Only 2 patients died of a total of 68 Eisenmenger patients (including DS) who received advanced therapy for a median period of 2.4
years (the vast majority of them were in class III or IV at baseline). Two-years overall survival rate was 91% in our study. However, 4 patients died within 6 months after baseline and effect of bosentan might not have been present. Bosentan is not expected to prevent arrhythmic events but rather progressive deterioration and right ventricular failure. In patients younger than 50 years, only 2 died of right ventricular failure. The majority of them died suddenly. Coppus et al showed that survival of adults with DS is generally lower compared to the general population due to other comorbid factors like dementia and impaired mobility. 29 In the present study, DS was not an independent predictor for survival, most probably due the relatively young patient population. The mean age of patients with DS was 10 years lower than patients without DS (36 vs 46 years). Hypothetically, the underlying congenital defect effects disease progression, however, the post hoc subgroup analysis of the BREATHE-5 study by Berger et al showed that effect of bosentan treatment was similar in Eisenmenger patients with atrial septal defects and patients with ventricular septal defects. 30 
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The present study is limited by the lack of a placebo group and the heterogeneity of underlying diagnoses e.g. patients with and without the DS, patients with and without Eisenmenger syndrome, patients with and without closed defects and the variety of defects. Second limitation is the lacking data on time from PAH diagnosis to study inclusion. Most patients had PAH many years before study inclusion. Thirdly, the 6MWT and the SF-36 are not validated in patients with DS.
Therefore, definite conclusions on long-term treatment effect of bosentan should be taken with caution in these patients. Another limitation is that not all echocardiographic measurements could be performed in patients with complex cardiac geometry and intra-and inter-observer variability testing was not carried out, however all echocardiograms and analyzing were performed by 1 single observer.
Finally, the present study was limited by the lack of hemodynamic data like pulmonary vascular resistance and pulmonary artery pressure. We may assume that PAH diagnosis was made in the past in most patients by right heart catheterisation, except probably for some high risk patients with Eisenmenger syndrome, in whom right heart catheterisation was not routinely performed as pulmonary arterial hypertension is clearly evident on echocardiography and these patients are known to be at high risk for complications due to this invasive procedure cardiac catheterization. Due to this complication risk cardiac catheterization was not performed to evaluate treatment effect at follow-up.
In conclusion, we demonstrate a prolonged beneficial effect of bosentan treatment on exercise capacity, stroke volume and quality of life in patients without DS. However the mortality rate of 20% of patients after 4 years of follow-up remains high.
